scholarly journals Transmyocardial revascularization devices: technology update

2014 ◽  
pp. 11 ◽  
Author(s):  
Keith Horvath ◽  
Bogdan Kindzelski ◽  
Yifu Zhou
Keyword(s):  
Transmyocardial Revascularization

Robotic-Assisted Off-Pump Sole Transmyocardial Revascularization: Case Report

2004 ◽  
Vol 7 (2) ◽  
pp. E130-E131 ◽  
Author(s):  
Kurt E. Wehberg ◽  
James C. Todd ◽  
J. Stephens Julian ◽  
Nicholas L. Ogburn ◽  
Edward H. Klopp ◽  
...  
Keyword(s):  
Case Report ◽  
Robotic Assisted ◽  
Off Pump ◽  
Transmyocardial Revascularization

Early Results of Transmyocardial Revascularization With a Holmium Laser

1998 ◽  
Vol 65 (3) ◽  
pp. 700-704 ◽  
Author(s):  
Aldo Milano ◽  
Stefano Pratali ◽  
Giuseppe Tartarini ◽  
Rita Mariotti ◽  
Marco De Carlo ◽  
...  
Keyword(s):  
Holmium Laser ◽  
Early Results ◽  
Transmyocardial Revascularization

Preconditioning of the Heart Following Transmyocardial Revascularization

2015 ◽  
pp. 305-310
Author(s):  
Chartchai Kositprapa ◽  
On Topaz ◽  
Arun Samidurai ◽  
Shinji Okubo ◽  
Vigneshwar Kasirajan ◽  
...  
Keyword(s):  
Transmyocardial Revascularization

Fast Track Minimally Invasive Transmyocardial Revascularization

2009 ◽  
Vol 4 (4) ◽  
pp. 217-220
Author(s):  
Kurt E. Wehberg ◽  
Debra Jackson ◽  
Joseph Walters ◽  
Brandon Redmond ◽  
James C. Todd ◽  
...  
Keyword(s):  
Length Of Stay ◽  
Ejection Fraction ◽  
Minimally Invasive ◽  
Fast Track ◽  
Lower Lobe ◽  
Hospital Length Of Stay ◽  
Perioperative Morbidity ◽  
Prolonged Length ◽  
Transmyocardial Revascularization ◽  
Management Protocol

Objective We evaluated the initial results of a fast-track discharge protocol for patients undergoing minimally invasive transmyocardial revascularization (MiTMR). Methods Fifteen male patients, aged 64.5 ± 9.2 years, with an ejection fraction of 46.8% ± 9.9%, underwent MiTMR through a mini-left anterior thoracotomy aided by robotic-controlled thoracoscopic assistance. A postoperative management protocol included immediate extubation, early chest tube and pulmonary artery catheter removal, and mobilization within 12 hours. Results There were no operative arrhythmias or in-hospital mortalities. Three of 15 patients developed left lower lobe atelectasis, delaying discharge between 2 and 5 days. Overall hospital length of stay was 1.4 ± 1.2 days, although 12 of 15 patients (80%) were discharged to home in 23 hours. Mild-moderate cardiomyopathy (ejection fraction 30%–50%) was not associated with prolonged length of stay. Mean hospital profit margin was $1882.50. One 30-day readmission occurred on day 23 for rapid atrial fibrillation, and one death occurred on day 11. Conclusions Despite these high-risk patients having end-staged, ischemic coronary artery disease, most MiTMR patients can be discharged to home in less than 24 hours. Perioperative morbidity and mortality rates are relatively low, and hospital profit margins are modest.

Transmyocardial revascularization: 5-year follow-up of a prospective, randomized multicenter trial

2004 ◽  
Vol 77 (4) ◽  
pp. 1228-1234 ◽  
Author(s):  
Keith B Allen ◽  
Robert D Dowling ◽  
William W Angell ◽  
Deepak M Gangahar ◽  
Tommy L Fudge ◽  
...  
Keyword(s):  
Multicenter Trial ◽  
Transmyocardial Revascularization

scholarly journals Transmyocardial revascularization to enhance myocardial vasculogenesis and hemodynamic function

2008 ◽  
Vol 135 (2) ◽  
pp. 283-291.e1 ◽  
Author(s):  
Pavan Atluri ◽  
Corinna M. Panlilio ◽  
George P. Liao ◽  
Eric E. Suarez ◽  
Ryan C. McCormick ◽  
...  
Keyword(s):  
Transmyocardial Revascularization ◽  
Hemodynamic Function

Combined transmyocardial revascularization and cell-based angiogenic gene therapy increases transplanted cell survival

2007 ◽  
Vol 293 (6) ◽  
pp. H3311-H3316 ◽  
Author(s):  
Dan Spiegelstein ◽  
Christopher Kim ◽  
Yaoguang Zhang ◽  
Guangming Li ◽  
Richard D. Weisel ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Growth Factor ◽  
Cell Survival ◽  
Bone Marrow Cells ◽  
Combined Therapy ◽  
Left Ventricular ◽  
Lv Function ◽  
Angiogenic Growth Factors ◽  
Myocardial Repair ◽  
Transmyocardial Revascularization

We hypothesized that pretreatment of an infarcted heart by mechanical transmyocardial revascularization (TMR) before transplantation of bone marrow cells (BMCs) or BMC-expressing angiogenic growth factors would increase transplanted BMC survival and enhance myocardial repair. Female Lewis rats underwent coronary ligation 3 wk before creation of 10 needle TMR channels (3 groups) or no TMR (3 groups), followed by transplantation of 3 × 106 male donor BMCs, BMC transfected with vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and insulin-like growth factor-1 (IGF-1) (BMC + VBI), or medium alone. At 1, 3, and 7 days, we evaluated transplanted cell survival, vascular densities, and left ventricular (LV) function ( N = 4 per group × 6 groups × 3 time points). At 3 days, vascular densities in the scar were increased by TMR + BMC + VBI and by BMC + VBI ( P < 0.05), and at 7 days, vascular densities were greatest in rats receiving TMR + BMC + VBI ( P < 0.05). Transplanted cell survival at 3 and 7 days was increased by TMR and by BMC + VBI. Combined therapy with TMR + BMC + VBI resulted in the greatest cell survival at 3 days ( P < 0.05) versus BMC. After 7 days, LV ejection fraction (LVEF) was lowest in rats receiving neither BMC nor TMR and greatest in rats receiving TMR + BMC + VBI ( P = 0.004). We concluded that mechanical pretreatment of infarcted myocardium by TMR enhances the effect of subsequent cell-based gene therapy on transplanted cell survival, angiogenesis, and LV function. Scar pretreatment with TMR combined with cell-based multigene therapy may maximize myocardial repair.

Sign in / Sign up

Export Citation Format

Share Document